Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
You may also be interested in...
At meeting on Pacira's Exparel, advisory committee members warn against rushing to adopt products purported to reduce opioid consumption absent long-term longitudinal data showing beneficial public health impacts and clinical data linking reduced opioid use to functional outcomes or other clinical benefit.
The specialty pharma laid out plans for driving future growth after completing two acquisitions earlier this year. Two of the key drivers will be drugs acquired in those deals – along with more business development.
Through the Catalyst Awards program at its Clinical and Translational Science Institute, UCSF will give MedImmune access to a broad range of discovery and preclinical opportunities under a three-year agreement. Plus, Mallinckrodt buys Cadence, Debiopharm acquires Affinium’s antibiotics program, and more.